Antibiotics Market Report by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others), Drug Class (Cephalosporin, Penicillin, Fluoroquinolone,

Antibiotics Market Report by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others), Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, and Others), Spectrum of Activity (Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Topical, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region 2024-2032

The global antibiotics market size reached US$ 51.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.

Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.

At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market. Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.

Antibiotics Market Trends/Drivers:

Rising prevalence of infectious diseases

There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics. There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.

Increasing occurrence of antimicrobial resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.

Technological advancements in antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods. Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.

Antibiotics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others

Cell wall synthesis inhibitors represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the action mechanism. This includes cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. According to the report, cell wall synthesis represented the largest segment.

Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Breakup by Drug Class:

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolide
• Carbapenem
• Aminoglycoside
• Others

Penicillin accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. According to the report, penicillin represented the largest segment.

Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Breakup by Spectrum of Activity:

• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics hold the biggest market share

The report has provided a detailed breakup and analysis of the market based on the spectrum of activity. This includes broad-spectrum antibiotics and narrow-spectrum antibiotics. According to the report, broad-spectrum antibiotics represented the largest segment.

Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Breakup by Route of Administration:

• Oral
• Parenteral
• Topical
• Others

Parenteral dominates the market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, parenteral, topical, and others. According to the report, parenteral represented the largest segment.

Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Breakup by End User:

• Hospitals
• Specialty Clinics
• Others

Hospitals accounted for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.

Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represented the largest market.

Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Allergan Plc (AbbVie Inc.)
• Basilea Pharmaceutica AG
• GlaxoSmithKline Plc
• Johnson & Johnson
• Melinta Therapeutics
• Merck & Co. Inc.
• Nabriva Therapeutics Plc
• Paratek Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi SA
• Spero Therapeutics
• Tetraphase Pharmaceuticals

Recent Developments:

• n 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline’s (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.
• n January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.

Key Questions Answered in This Report

1. How big is the global antibiotics market?

2. What is the expected growth rate of the global antibiotics market during 2024-2032?

3. What are the key factors driving the global antibiotics market?

4. What has been the impact of COVID-19 on the global antibiotics market?

5. What is the breakup of the global antibiotics market based on the action mechanism?

6. What is the breakup of the global antibiotics market based on the drug class?

7. What is the breakup of the global antibiotics market based on the spectrum of activity?

8. What is the breakup of the global antibiotics market based on the route of administration?

9. What is the breakup of the global antibiotics market based on the end user?

10. What are the key regions in the global antibiotics market?

11. Who are the key players/companies in the global antibiotics market?